Sugi Predict

Sugi Predict / Compounds / SCHEMBL1625643

SCHEMBL1625643

SCHEMBL1625643

CC(C)(C)OC(=O)CNC(=O)C1=C(O)c2cc(F)ccc2C(C)(C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SPR P35270 1/20 0.41
▸ PTPRC P08575 2/20 0.41
▸ MAPK14 Q16539 2/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ CCNT1 O60563 1/20 0.33
▸ HIF1A Q16665 3/20 0.32
▸ MAPT P10636 1/20 0.32
▸ PDK2 Q15119 1/20 0.31
▸ DGAT2 Q96PD7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627211 0.92 PTPRC (0.43) SPRPTPRCMAPK14EGLN1CCNT1
SCHEMBL1628499 0.88 SPR (0.42) SPRPTPRCEGLN1MAPT
SCHEMBL1626236 0.88 SPR (0.40) SPRPTPRCEGLN1
SCHEMBL1626674 0.87 SPR (0.41) SPRPTPRCEGLN1MAPT
SCHEMBL1625319 0.87 SPR (0.41) SPRPTPRCEGLN1MAPT
SCHEMBL1627824 0.87 PTPRC (0.40) SPRPTPRCEGLN1HIF1AMAPT
SCHEMBL12720391 0.85 SPR (0.44) SPRMAPK14EGLN1HIF1A
SCHEMBL1626466 0.85 SPR (0.47) SPRMAPK14EGLN1HIF1A
SCHEMBL1626700 0.85 SPR (0.40) SPRPTPRCEGLN1MAPT
SCHEMBL3840046 0.85 SPR (0.39) SPRMAPK14EGLN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 — — US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 — — US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 — — US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 — — EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 — — US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN SPR 754/4885PTPRC 4014/4885MAPK14 3629/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN SPR 754/4885PTPRC 4014/4885MAPK14 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.